Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment - PubMed (original) (raw)
Review
. 2012 Nov;304(9):707-17.
doi: 10.1007/s00403-012-1266-9. Epub 2012 Jul 29.
Affiliations
- PMID: 22843024
- DOI: 10.1007/s00403-012-1266-9
Review
Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment
Sonia A Lamel et al. Arch Dermatol Res. 2012 Nov.
Abstract
There is a need to better define how the efficacy of investigational drugs is affected by study design, implementation, and placebo responses in randomized controlled trials. The improvements observed in placebo groups within trials examining psoriasis treatments may be partially due to study design and implementation. We conducted a systematic review of randomized placebo-controlled trials assessing the efficacy of biologics in the treatment of psoriasis and psoriatic arthritis to evaluate rates of placebo and active drug responders to determine specific factors within study design that may contribute to placebo responses. We included randomized, placebo-controlled trials of etanercept, infliximab, adalimumab, golimumab, ustekinumab, alefacept, and efalizumab that utilized Psoriasis Area Severity Index as an outcomes measure. We compared the rates of the placebo treatment arm versus the active drug arm achieving 75 % improvement of Psoriasis Area Severity Index. 31 trials involving 8285 active treatment and 3999 placebo patients were included. Rates of placebo responders (4.14 %) were significantly lower than active drug responders (48.4 %). The overall odds ratio calculated was 23.94 (p < 0.0001, 95 % CI 16.02-35.76). Binomial regression models showed that treatment indication, randomization fraction, a PASI inclusion requirement, and the time period of outcomes measure documentation affect placebo responses. Placebo responses seen in randomized controlled trials evaluating biologics in the treatment of psoriasis are not likely due to a physiologic mechanism, but may be secondary to chronic disease course and factors of clinical trial design and implementation.
Similar articles
- Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K, Burden AD, Eaton JN, Hawkins NS. Reich K, et al. Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Br J Dermatol. 2012. PMID: 21910698 Review. - Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM. McInnes IB, et al. J Comp Eff Res. 2018 Nov;7(11):1107-1123. doi: 10.2217/cer-2018-0075. Epub 2018 Sep 19. J Comp Eff Res. 2018. PMID: 30230361 - Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Schmitt J, et al. Br J Dermatol. 2008 Sep;159(3):513-26. doi: 10.1111/j.1365-2133.2008.08732.x. Epub 2008 Jul 9. Br J Dermatol. 2008. PMID: 18627372 Review. - Comparative efficacy of biologics in psoriasis: a review.
Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL. Kim IH, et al. Am J Clin Dermatol. 2012 Dec 1;13(6):365-74. doi: 10.2165/11633110-000000000-00000. Am J Clin Dermatol. 2012. PMID: 22967166 Review. - Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Brimhall AK, et al. Br J Dermatol. 2008 Aug;159(2):274-85. doi: 10.1111/j.1365-2133.2008.08673.x. Epub 2008 Jun 10. Br J Dermatol. 2008. PMID: 18547300 Review.
Cited by
- Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A, Borg E, Warren RB. Sawyer LM, et al. PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019. PLoS One. 2019. PMID: 31412060 Free PMC article. - Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement.
Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ, Guttman-Yassky E. Leshem YA, et al. J Eur Acad Dermatol Venereol. 2019 May;33(5):807-815. doi: 10.1111/jdv.15480. Epub 2019 Mar 12. J Eur Acad Dermatol Venereol. 2019. PMID: 30859656 Free PMC article. - Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Hebert AA, Glaser DA, Green L, Werschler WP, Forsha DW, Drew J, Gopalan R, Pariser DM. Hebert AA, et al. Pediatr Dermatol. 2019 Jan;36(1):89-99. doi: 10.1111/pde.13723. Epub 2018 Nov 19. Pediatr Dermatol. 2019. PMID: 30451318 Free PMC article. Clinical Trial. - Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB. Sawyer LM, et al. J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31. J Eur Acad Dermatol Venereol. 2019. PMID: 30289198 Free PMC article. - Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B; NEPTUNE investigators. Papp KA, et al. Br J Dermatol. 2019 Jun;180(6):1352-1360. doi: 10.1111/bjd.17195. Epub 2018 Nov 2. Br J Dermatol. 2019. PMID: 30207587 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical